These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28025965)

  • 21. Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study.
    Kjeldsen SE; Dzongowski P; Li N; Wang L; Radlmaier A
    J Clin Pharm Ther; 2016 Dec; 41(6):695-702. PubMed ID: 27670639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
    Bönner G; Landers B; Bramlage P
    Vasc Health Risk Manag; 2011; 7():85-95. PubMed ID: 21415922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproducibility of nifedipine absorption from GITS tablets: comparison of single-dose pharmacokinetics using 10, 20, 40 and 60 mg nifedipine.
    Tateishi T; Okumura K; Orii Y; Tanaka T
    Int J Clin Pharmacol Ther; 2004 Jan; 42(1):58-62. PubMed ID: 14756389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration.
    Anschütz M; Wonnemann M; Schug B; Toal C; Donath F; Pontius A; Pauli K; Brendel E; Blume H
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):158-70. PubMed ID: 20137768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine?
    Toal CB
    J Cardiovasc Pharmacol; 2004 Jul; 44(1):82-6. PubMed ID: 15175561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers.
    El-Masry SM; El-Khodary NM
    Drug Res (Stuttg); 2020 Feb; 70(2-03):91-96. PubMed ID: 31746448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: the FOCUS Study.
    Park JB; Shin JH; Kim DS; Youn HJ; Park SW; Shim WJ; Park CG; Kim DW; Lee HY; Choi DJ; Rim SJ; Lee SY; Kim JH;
    Clin Ther; 2016 Apr; 38(4):832-42. PubMed ID: 26996246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.
    Fujikawa K; Hasebe N; Kikuchi K;
    Hypertens Res; 2005 Jul; 28(7):585-91. PubMed ID: 16335887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.
    Liu J; Wu L; Hu X; Wu G; Zheng Y; Zhou H; Zhai Y; Zhu M; ShenTu J
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):573-81. PubMed ID: 25828636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.
    Croom KF; Wellington K
    Drugs; 2006; 66(4):497-528. PubMed ID: 16597165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina.
    Walker JM; Curry PV; Bailey AE; Steare SE
    Int J Cardiol; 1996 Feb; 53(2):117-26. PubMed ID: 8682597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results.
    Kjeldsen SE; Sica D; Haller H; Cha G; Gil-Extremera B; Harvey P; Heyvaert F; Lewin AJ; Villa G; Mancia G;
    J Hypertens; 2014 Dec; 32(12):2488-98; discussion 2498. PubMed ID: 25144296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.
    Dudkowski C; Karim A; Zhao Z; Alonso AB; Garg D; Preston RA
    J Clin Pharmacol; 2018 Jan; 58(1):48-56. PubMed ID: 28750149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 24-hour ambulatory blood pressure data in hypertensive patients switched from nifedipine-GITS to nifedipine-CC.
    Wurdeman RL; Mooss AN; Mohiuddin SM; Lucas BD; Ryschon KL; Hilleman DE
    Pharmacotherapy; 1999 Jan; 19(1):94-100. PubMed ID: 9917082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
    Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
    Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
    Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment.
    Heinig R; Lambelet M; Nagelschmitz J; Alatrach A; Halabi A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):619-628. PubMed ID: 30825073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.